Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2025-04-02 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors, referencing regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It discusses compliance with independence requirements but does not contain financial data, audit results, or detailed management reports. It is a governance-related disclosure about board members' independence rather than a full governance report or management change announcement. Given the content and length, it fits best under Governance Information (CGR).
2025-04-02 Chinese
马应龙关于2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from a company regarding its 2024 annual profit distribution plan, including details on cash dividends per share, total dividend amount, and related shareholder meeting approvals. It does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution specifics and procedural information. The document length is 1944 characters, which is relatively short and typical for a dividend announcement. It explicitly states the dividend amount, payment basis, and that the plan requires shareholder approval. This matches the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders. It is not an Annual Report (10-K), Earnings Release (ER), or other financial report type, nor is it a report publication announcement or regulatory filing. Therefore, the correct classification is DIV with high confidence.
2025-04-02 Chinese
马应龙2024年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度审计委员会工作报告" (2024 Audit Committee Work Report) of 马应龙药业集团股份有限公司. It details the audit committee's activities, meetings, evaluations of external and internal audits, review of financial reports for various periods in 2024, and overall assessment of audit work. It does not contain the full annual report or financial statements but rather focuses on the audit committee's oversight and supervisory role. The document length is 2576 characters, which is relatively short and consistent with a committee work report rather than a full annual report or audit report. It is not a certification or a simple announcement but a detailed committee report on audit activities. Therefore, the best fitting category is Audit Report / Information (AR), which covers standalone audit reports and related supervisory information excluding full annual reports. FY 2024
2025-04-02 Chinese
马应龙第十一届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 11th Board of Directors of Mayinglong Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals related to the 2024 fiscal year, such as the General Manager's report, Audit Committee reports, financial results, profit distribution plan, annual report, internal control evaluation, ESG report, and other corporate governance matters. The document references that the detailed reports are published separately on the Shanghai Stock Exchange website and newspapers, indicating this document itself is a board meeting resolution announcement rather than the full reports. The document contains actual voting results and decisions made by the board, which fits the category of Board/Management Information (MANG). It is not a full annual report (10-K), audit report (AR), or other report types, but a formal announcement of board decisions and management reports approval. The document length is 3591 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2025-04-02 Chinese
马应龙2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度内部控制评价报告' which translates to '2024 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, their identification, and remediation status. The document contains detailed internal control assessment results, standards, and conclusions, indicating it is a comprehensive report on internal control evaluation rather than a brief announcement or certification. It is not an annual report (10-K), earnings release, or other financial statement but specifically focuses on internal control evaluation, which aligns with the category of Audit Report / Information (AR). The document length is 4092 characters, which is substantial and contains substantive content, not just a notice or certification. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2024
2025-04-02 Chinese
马应龙第十一届监事会第十三次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Mayinglong Pharmaceutical Group Co., Ltd. regarding the approval of the 2024 Annual Report, the 2024 Internal Control Evaluation Report, and accounting policy changes. It states that the detailed reports are published separately on April 3, 2025, in newspapers and on the Shanghai Stock Exchange website. The document itself is short (1358 characters) and does not contain the full annual report or internal control report but rather announces the resolutions and points to where the full reports can be found. According to the 'Menu vs Meal' rule, this is an announcement of reports, not the reports themselves. Therefore, the correct classification is Report Publication Announcement (RPA).
2025-04-02 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.